NIH Grant Program (with Johns Hopkins)

About CTT Pharma

CTT Pharma is a development-stage biotechnology company with a mission to improve patient quality of life through its innovative micelle-encapsulated oral thin-film delivery platform. Key achievements include a robust global patent portfolio, a completed PCAOB audit enabling an OTCQB uplist, and a pending NIH grant proposal with Johns Hopkins University for a smoking cessation clinical trial. The company's near-term strategy focuses on capital-efficient progression towards manufacturing and SEC reporting status in 2025/2026, initially targeting the nutraceutical and nicotine replacement therapy markets as regulatory and commercial pathways are established.

Therapeutic Areas

Other Smoking Cessation Drugs